India Pharma Outlook Team | Wednesday, 18 May 2022
HempStreet, India's first research to retail venture in the ayurvedic cannabis sector has partnered with Gynica, an R&D company based out of Israel focused on changing the culture of gynaecological treatment through clinically proven, cannabinoid-based solutions.
The partnership will benefit the companies to strengthen their R&D capabilities and to develop clinically-proven, robust phytopharmaceutical products to improve menstrual health and tackle other mass ailments. Established in 2019, HempStreet has been leveraging the growing popularity of the age-old science of Ayurveda to manufacture ‘natural relief’ products from cannabis to treat chronic pain and menstrual health. HempStreet has made significant progress on that front
via its flagship menstrual pain product Trailokya Vijaya Vati, that has shipped over 4 million doses across India. Both Gynica and HempStreet have a strong focus on phytopharmaceutical products and together, the companies will co-develop medical products for the Indian market to tackle ailments specifically related to womens’ health. Abhishek Mohan, founder & CEO, HempStreet, said, “This partnership is also representative of the focus of biotech innovation in India and Israel, that both share the same passion for phytopharmaceutical medicines and to solve for the world.
We have been able to provide a solution to scores of women via our medicines and nationwide partner clinic network. We are confident this partnership will usher in a new era of women's healthcare not just for India but the world.” Yotam Hod , CEO, Gynica said, “We are confident that this valuable collaboration will help bring relief to women throughout the world, by leveraging Gynica's clinical validation methodologies, with Hempstreet's plethora of knowledge in the field of Ayurveda for women's health.” The company said together with Gynica, HempStreet intends to become a leader in providing polyherbal-based medication for mass ailments worldwide.
, CDSCO.jpg)
